Compare KRNT & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRNT | FDMT |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.7M | 695.3M |
| IPO Year | 2014 | 2019 |
| Metric | KRNT | FDMT |
|---|---|---|
| Price | $16.80 | $12.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $25.00 | ★ $28.09 |
| AVG Volume (30 Days) | 315.0K | ★ 933.5K |
| Earning Date | 11-18-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $7.48 | N/A |
| Revenue Next Year | $7.27 | $55.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $12.26 | $6.96 |
| 52 Week High | $19.78 | $16.93 |
| Indicator | KRNT | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 48.92 |
| Support Level | $14.56 | $8.68 |
| Resistance Level | $16.80 | $13.64 |
| Average True Range (ATR) | 0.68 | 1.02 |
| MACD | -0.19 | 0.05 |
| Stochastic Oscillator | 30.20 | 58.89 |
Kornit Digital Ltd is a developer and provider of digital solutions for the printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value-added services that enable large-scale printing of short-run complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink, and other consumables, and services, including software subscriptions. The company geographically operates in the U.S., EMEA, Asia Pacific, and other countries. It derives maximum revenue from the U.S.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).